Standard treatments recommended by NCCN Guidelines for this setting include fruquintinib (Fruzaqla), regorafenib (Stivarga), ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

The multi-day nature of standard chemotherapy regimens used in extensive-stage small cell lung cancer (ES-SCLC) creates ...

Luspatercept-aamt (Reblozyl) is among National Comprehensive Cancer Network Guideline recommendations for low-risk MDS.

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk ...

The FDA has converted its 2024 accelerated approval of tarlatamab-dlle (Imdelltra) for the treatment of adults with extensive ...

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...

Biomarker testing for patients with ovarian cancer should be completed both in the upfront setting and through disease ...

Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic ...

Panelists discuss how specific talquetamab-related side effects like skin peeling, nail changes, and rashes can be effectively managed through targeted interventions including topical treatments, ...

Panelists discuss how healthcare providers can develop comprehensive management protocols for talquetamab-related toxicities by consulting with specialists, gathering patient feedback, and creating ...